title: A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
abstract: BACKGROUND
  A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer.
  
  
  METHODS
  Twenty-five patients with untreated brain metastases from breast cancer were treated with cisplatin (at a dose of 20 mg/m(2)/day, Days 1-5) and vinorelbine (6-mg/m(2) bolus on Day 1 and 6 mg/m(2)/day continuous infusion on Days 1-5) chemotherapy combined with concurrent 30-gray fractionated external-beam radiotherapy. Chemotherapy was given at 3-week intervals for a total of 4 cycles. Primary endpoint was the rate of radiologic response of brain metastases.
  
  
  RESULTS
  Complete response in the brain was observed in 3 patients, and partial response was noted in 16 patients, yielding a 76% response rate in the brain. The overall systemic response rate was 44%. Progression-free and overall survival were 3.7 months and 6.5 months, respectively. Overall toxicity was acceptable; nonhematologic grade 3-4 events were noted in 5 (20%) patients, and there were no toxic deaths.
  
  
  CONCLUSIONS
  Concurrent chemoradiation with cisplatin and vinorelbine for brain metastases from breast cancer appears to be active and well tolerated.
authors.affiliation: Multidisciplinary Medical Oncology Day Unit, Edouard Herriot Hospital, Lyon, France.
authors.forename: Philippe A
authors.initials: PA
authors.lastname: Cassier
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Sunyach
authors.forename: Laurence
authors.initials: L
authors.lastname: Lancry
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Guastalla
authors.forename: Céline
authors.initials: C
authors.lastname: Ferlay
authors.forename: Frédéric
authors.initials: F
authors.lastname: Gomez
authors.forename: Hervé
authors.initials: H
authors.lastname: Curé
authors.forename: Alain
authors.initials: A
authors.lastname: Lortholary
authors.forename: Line
authors.initials: L
authors.lastname: Claude
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Thomas
authors.initials: T
authors.lastname: Bachelot
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine